HDAC9 and rhabdomyosarcoma: Patient-derived tumors were dissociated and cultured for in vitro drug sensitivity screening, which identified that HDAC and proteasome inhibitors had activity across multiple tumor types and cell lines and that a WEE1 inhibitor called AZD1775 was particularly active in rhabdomyosarcoma cells.